Uncategorized

MONTREAL, April 3, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that new additional follow-up data from its latest NAP-based combination trials in HBV infection (REP 401 study) and HBV / HDV co-infection (REP 301-LTF study) will be presented at the 2018 International…

REP 2139 and TDF/ETV combine synergistically to establish control of cccDNA in the liver MONTREAL, December 20, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection announced today the publication of its in vivo study examining the efficacy of REP 2139 combined with…

MONTREAL, December 12, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection announced today the publication of its in vitro study of the activity of NAPs in various tissue culture models of HDV infection in the Journal of Virology (http://jvi.asm.org/content/early/2017/11/30/JVI.01416-17.long). This in vitro study was…

MONTREAL, November 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today its accepted oral presentation at the 2017 HEP DART meeting, to be held from December 3-7, 2017 in Kona, HI, USA (http://www.virology-education.com/event/upcoming/hep-dart-2017/).…

MONTREAL, November 9, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection announced today the publication of its analyses of the activity of NAPs in various rodent models of HBV infection in the journal Antiviral Research (http://www.sciencedirect.com/science/article/pii/S016635421730596X). These evaluations in rodent…

MONTREAL, November 6, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection and the INRS-Institut Armand-Frappier (INRS-IAF) of the Institut National de la Recherche Scientifique (INRS), announced today the formal establishment of a collaboration to identify the mechanisms of HBV subviral…

MONTREAL, October 23, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented today the first interim follow-up data from its REP 401 study at the 2017 meeting of the American Association for the Study of…

MONTREAL, Oct 10, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that its late breaking abstract describing the preliminary follow-up data from the ongoing REP 401 clinical trial has been accepted as a late-breaking presentation at the 2017 meeting of the American Association…

MONTREAL, October 2, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented an updated, comprehensive technology overview of its nucleic acid polymer (NAP) technology at the Inaugural “Targeting HBV Symposium” at the 2017 Discovery on…

MONTREAL, September 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the publication of its REP 301 study on the activity of REP 2139 and pegylated interferon α-2a (pegIFN) in The Lancet Gastroenterology…